Different human papillomavirus types share early natural history transitions in immunocompetent women

Sally N. Adebamowo & Nicole G Campos et al. · 2022-06-17

Abstract

Necessary stages of cervical carcinogenesis include acquisition of a carcinogenic human papillomavirus (HPV) type, persistence associated with the development of precancerous lesions, and invasion. Using prospective data from immunocompetent women in the Guanacaste HPV Natural History Study (NHS), the ASCUS‐LSIL Triage Study (ALTS) and the Costa Rica HPV Vaccine Trial (CVT), we compared the early natural history of HPV types to inform transition probabilities for health decision models. We excluded women with evidence of high‐grade cervical abnormalities at any point during follow‐up and restricted the analysis to incident infections in all women and prevalent infections in young women (aged <30 years). We used survival approaches accounting for interval‐censoring to estimate the time to clearance distribution for 20 529 HPV infections (64% were incident and 51% were carcinogenic). Time to clearance was similar across HPV types and risk classes (HPV16, HPV18/45, HPV31/33/35/52/58, HPV 39/51/56/59 and noncarcinogenic HPV types); and by age group (18‐29, 30‐44 and 45‐54 years), among carcinogenic and noncarcinogenic infections. Similar time to clearance across HPV types suggests that relative prevalence can predict relative incidence. We confirmed that there was a uniform linear association between incident and prevalent infections for all HPV types within each study cohort. In the absence of progression to precancer, we observed similar time to clearance for incident infections across HPV types and risk classes. A singular clearance function for incident HPV infections has important implications for the refinement of microsimulation models used to evaluate the cost‐effectiveness of novel prevention technologies.

Funding

NCI NIH HHS

N01 CN055159

NCI NIH HHS

N01 CN055158

NHGRI NIH HHS

U54 HG006947

NCI NIH HHS

N01 CN055156

NHGRI NIH HHS

U01 HG011717

NCI NIH HHS

P30 CA134274

NCI NIH HHS

N01 CN055154

NCI NIH HHS

N01 CP011005

NCI NIH HHS

N01 CN055155

NCI NIH HHS

N01 CN055153

NCI NIH HHS

T32 CA009168

NCI NIH HHS

N01 CN055157

World Health Organization

001

NCI NIH HHS

N01 CN055105

American Cancer Society

IRG‐18‐160‐16

National Cancer Institute

T32CA09168

National Human Genome Research Institute

1U54HG006947

National Human Genome Research Institute

P30CA134274

National Human Genome Research Institute

U01HG011717

U.S. Department of Health and Human Services

CN‐55153

U.S. Department of Health and Human Services

CN‐55154

U.S. Department of Health and Human Services

CN‐55156

U.S. Department of Health and Human Services

CN‐55157

U.S. Department of Health and Human Services

CN‐55158

U.S. Department of Health and Human Services

CN‐55159

U.S. Department of Health and Human Services

CN55105

U.S. Department of Health and Human Services

CN55155